Benzinga | Sep 20, 2021 01:46PM EDT

Incyte's Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada

* Health Canada has given conditional approval to Incyte Corporation's (NASDAQ:INCY) Pemazyre (pemigatinib) to treat cholangiocarcinoma.

* Cholangiocarcinoma is a type of cancer that forms in the slender tubes (bile ducts) that carry the digestive fluid bile.

* The approval covers adults with previously treated, unresectable locally advanced, or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.

* Pemazyre is a selective fibroblast growth factor receptor (FGFR) inhibitor.

* The conditional approval is based on FIGHT-202 study data that resulted in an overall response rate (ORR) of 35.5% and a median duration of response of 9.1 months.

* Related content: Benzinga's Full FDA Calendar.

* Price Action: INCY stock is up 1.24% at $76.93 during the market session on the last check Monday.